Barrier takes second dermatologic product into Canada

Princeton, N.J.-Barrier Therapeutics Inc., a pharmaceutical company that specializes in dermatologic products, is now marketing and selling Vaniqa Cream (SkinMedica) in Canada.

Vaniqa (eflornithine hydrochloride) is a topical prescription product used for slowing the growth of excessive facial hair in women. It has been approved for such use by Health Canada. Princeton-based Barrier acquired the exclusive rights to distribute Vaniqa in Canada from Shire Pharmaceutical Contracts Ltd. in June.

Barrier also sells and markets another product, Solagé Topical Solution (Galderma) for age spots, in Canada.